The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
Purpose. To determine the effect of epiretinal membranes (ERM) on the treatment response and the number of intravitreal bevacizumab injections (IVB) in patients with neovascular age-related macular degeneration (nAMD). Methods. A retrospective chart review was performed on 63 eyes of 63 patients. Th...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2013/958724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850165977129418752 |
|---|---|
| author | Zeynep Alkin Abdullah Ozkaya Ozen Ayranci Osmanbasoglu Alper Agca Yalcin Karakucuk Ahmet Taylan Yazici Ahmet Demirok |
| author_facet | Zeynep Alkin Abdullah Ozkaya Ozen Ayranci Osmanbasoglu Alper Agca Yalcin Karakucuk Ahmet Taylan Yazici Ahmet Demirok |
| author_sort | Zeynep Alkin |
| collection | DOAJ |
| description | Purpose. To determine the effect of epiretinal membranes (ERM) on the treatment response and the number of intravitreal bevacizumab injections (IVB) in patients with neovascular age-related macular degeneration (nAMD). Methods. A retrospective chart review was performed on 63 eyes of 63 patients. The patients were divided into AMD group (n=35) and AMD/ERM group (n=28). Best corrected visual acuity (BCVA) and central retinal thickness (CRT), as well as the number of injections, were evaluated. Results. There was a significant improvement in BCVA at 3 months for the AMD and AMD/ERM groups (P=0.02, P=0.03, resp.). At 6, 12, and 18 months, BCVA did not change significantly in either of the groups compared to baseline (P>0.05 for all). At 3, 6, 12, and 24 months, the AMD group had an improvement in BCVA (logMAR) of 0.09, 0.06, 0.06, and 0.03 versus 0.08, 0.07, 0.05, and 0.03 for the AMD/ERM group (P=0.29, P=0.88, P=0.74, P=0.85, resp.). A significant decrease in CRT occurred in both groups for all time points (P<0.001 for all). The change in CRT was not statistically different between the two groups at all time points (P>0.05 for all). The mean number of injections over 24 months was 8.8 in the AMD group and 9.2 in the AMD/ERM group (P=0.76). Conclusion. During 24 months, visual and anatomical outcomes of IVB in nAMD patients were comparable with those in nAMD patients with ERM with similar injection numbers. |
| format | Article |
| id | doaj-art-dae97e0e2d904aadaa2f939ca85c7a80 |
| institution | OA Journals |
| issn | 1537-744X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-dae97e0e2d904aadaa2f939ca85c7a802025-08-20T02:21:35ZengWileyThe Scientific World Journal1537-744X2013-01-01201310.1155/2013/958724958724The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal BevacizumabZeynep Alkin0Abdullah Ozkaya1Ozen Ayranci Osmanbasoglu2Alper Agca3Yalcin Karakucuk4Ahmet Taylan Yazici5Ahmet Demirok6Beyoglu Eye Training and Research Hospital, Bereketzade Cami Sok No. 2 Beyoglu, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Bereketzade Cami Sok No. 2 Beyoglu, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Bereketzade Cami Sok No. 2 Beyoglu, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Bereketzade Cami Sok No. 2 Beyoglu, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Bereketzade Cami Sok No. 2 Beyoglu, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Bereketzade Cami Sok No. 2 Beyoglu, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Bereketzade Cami Sok No. 2 Beyoglu, Istanbul, TurkeyPurpose. To determine the effect of epiretinal membranes (ERM) on the treatment response and the number of intravitreal bevacizumab injections (IVB) in patients with neovascular age-related macular degeneration (nAMD). Methods. A retrospective chart review was performed on 63 eyes of 63 patients. The patients were divided into AMD group (n=35) and AMD/ERM group (n=28). Best corrected visual acuity (BCVA) and central retinal thickness (CRT), as well as the number of injections, were evaluated. Results. There was a significant improvement in BCVA at 3 months for the AMD and AMD/ERM groups (P=0.02, P=0.03, resp.). At 6, 12, and 18 months, BCVA did not change significantly in either of the groups compared to baseline (P>0.05 for all). At 3, 6, 12, and 24 months, the AMD group had an improvement in BCVA (logMAR) of 0.09, 0.06, 0.06, and 0.03 versus 0.08, 0.07, 0.05, and 0.03 for the AMD/ERM group (P=0.29, P=0.88, P=0.74, P=0.85, resp.). A significant decrease in CRT occurred in both groups for all time points (P<0.001 for all). The change in CRT was not statistically different between the two groups at all time points (P>0.05 for all). The mean number of injections over 24 months was 8.8 in the AMD group and 9.2 in the AMD/ERM group (P=0.76). Conclusion. During 24 months, visual and anatomical outcomes of IVB in nAMD patients were comparable with those in nAMD patients with ERM with similar injection numbers.http://dx.doi.org/10.1155/2013/958724 |
| spellingShingle | Zeynep Alkin Abdullah Ozkaya Ozen Ayranci Osmanbasoglu Alper Agca Yalcin Karakucuk Ahmet Taylan Yazici Ahmet Demirok The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab The Scientific World Journal |
| title | The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab |
| title_full | The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab |
| title_fullStr | The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab |
| title_full_unstemmed | The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab |
| title_short | The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab |
| title_sort | role of epiretinal membrane on treatment of neovascular age related macular degeneration with intravitreal bevacizumab |
| url | http://dx.doi.org/10.1155/2013/958724 |
| work_keys_str_mv | AT zeynepalkin theroleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT abdullahozkaya theroleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT ozenayranciosmanbasoglu theroleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT alperagca theroleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT yalcinkarakucuk theroleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT ahmettaylanyazici theroleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT ahmetdemirok theroleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT zeynepalkin roleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT abdullahozkaya roleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT ozenayranciosmanbasoglu roleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT alperagca roleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT yalcinkarakucuk roleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT ahmettaylanyazici roleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab AT ahmetdemirok roleofepiretinalmembraneontreatmentofneovascularagerelatedmaculardegenerationwithintravitrealbevacizumab |